Evidence map›Paper›PMID 34338761›Full record

Trial reportThe journals of gerontology. Series A, Biological sciences and medical sciences2022

Validation of a Deficit-Accumulation Frailty Index in the ASPirin in Reducing Events in the Elderly Study and Its Predictive Capacity for Disability-Free Survival.

Joanne Ryan, Sara Espinoza, Michael E Ernst, A R M Saifuddin Ekram, Rory Wolfe, Anne M Murray, Raj C Shah, Suzanne G Orchard, Sharyn Fitzgerald, Lawrence J Beilin and 5 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The journals of gerontology. Series A, Biological sciences and medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Relative impact of multidomain lifestyle interventions on deficit accumulation frailty over 24 months in the U.S. POINTER trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Trial
  2. Trial
  3. Associations Between Deficit Accumulation Frailty and Baseline Markers of Lifestyle in the U.S. POINTER Trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025
    Trial
  4. Serum Transaminases and Older Adults: Distribution and Associations With All-Cause Mortality.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Neural embedding of frailty in cognitively unimpaired aging and dementia across Latin America.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Protective role of parenthood on age-related brain function in mid- to late-life.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Joanne RyanSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0002-7039-6325
Sara EspinozaDivision of Geriatrics, Gerontology & Palliative Medicine, Sam and Ann Barshop Institute for Longevity and Aging Studies, UT Health San Antonio, Texas, USA.
Michael E ErnstDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, USA.
A R M Saifuddin EkramSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0003-4267-1286
Rory WolfeSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Anne M MurrayBerman Center for Clinical Outcomes and Research, Hennepin Health Research Institute and Division of Geriatrics, Department of Medicine, Hennepin Healthcare and University of Minnesota, Minneapolis, USA.
Raj C ShahDepartment of Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
Suzanne G OrchardSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Sharyn FitzgeraldSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Lawrence J BeilinSchool of Medicine, Royal Perth Hospital, University of Western Australia, Australia.
Stephanie A WardSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Jeff D WilliamsonGerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Anne B NewmanCenter for Aging and Population Health, University of Pittsburgh, Pennsylvania, USA.
John J McNeilSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Robyn L WoodsSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0003-1249-6149

Funding

ASPirin in Reducing Events in the ElderlyU01AG029824 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MCNEIL, JOHN JAMES, MURRAY, ANNE M · 2009 to 2018
$64.6M
Main Administrative CoreU19AG062682 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI CHAN, ANDREW T, MCNEIL, JOHN JAMES · 2019 to 2023
$42.9M
NIA NIH HHS U01 AG029824NIA NIH HHS U19 AG062682NIH HHS U01AG029824
6 · The paper itself

Abstract

Frailty is a state of heightened vulnerability and susceptibility to physiologic stressors that increases with age. It has shown increasing utility in predicting a range of adverse health outcomes. Here, we characterize a 67-item deficit-accumulation frailty index (FI) in 19 110 community-dwelling individuals in the ASPirin in Reducing Events in the Elderly clinical trial. Participants aged 65-98 years were recruited from the United States and Australia and were without diagnosed dementia and cardiovascular disease, and major physical disability. The median FI score was .10 (interquartile range: .07-.14) at baseline, and the prevalence of frailty (FI > .21) increased from 8.1% to 17.4% after 6 years. FI was positively associated with age, and women had significantly higher scores than men at all ages. The FI was negatively correlated with gait speed (r = -.31) and grip strength (r = -.46), and strongly associated with a modified Fried's frailty phenotype (p < .0001, for all comparisons). Frailty was associated with the primary composite outcome capturing independent life lived free of major disability and dementia, and increased the rate of persistent physical disability (hazard ratio: 21.3, 95% confidence interval: 15.6-28.9). It added significantly to the predictive capacity of these outcomes above age, sex, and ethnicity alone. The FI is thus a useful biomarker of aging even among relatively healthy older individuals and provides important information about an individual's vulnerability to and risk of disease.

Indexed as

DementiaFrailtyPersons with DisabilitiesAgedAged, 80 and overAspirinFemaleFrail ElderlyGeriatric AssessmentHumansMaleUnited StatesAspirinBiomarkerPhysical functionPreventive health care

Identifiers

PMID34338761
PMCPMC8751791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.